Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) (NCT02978716), a randomized phase 2 study. The primary outcome is Duration of Severe (Grade 4) Neutropenia (DSN) During Cycle 1.

2. Clinical Question

The clinical question focuses on a blood-count outcome during the first treatment cycle, rather than on a direct measure of tumor response. The trial also investigated possible effects on bone marrow and the immune system, as well as chemotherapy antitumor efficacy. The registry record lists overall survival, progression-free survival, response, treatment exposure, and dose-related outcomes among the secondary measures.

The design allows comparison of the chemotherapy-only regimen with two trilaciclib schedules. The schedules differed in when trilaciclib and chemotherapy were administered, so the comparisons concern specific treatment regimens, not an abstract effect of trilaciclib independent of schedule. The registry record does not report a formal statistical hypothesis for the primary question or a justification for selecting the sample size.

3. Trial Design

This was a randomized, open-label, parallel-group Phase 2 study. The registry record reports enrollment of 102 participants, randomly assigned in a 1:1:1 fashion to three groups. One group received gemcitabine and carboplatin on Days 1 and 8 of 21-day cycles. A second received trilaciclib before the same chemotherapy schedule on Days 1 and 8. A third received trilaciclib on Days 1, 2, 8, and 9, with chemotherapy on Days 2 and 9. The registry record describes the trial as having screening, treatment, and survival follow-up phases.

Open-label means treatment assignment was not masked. The allocation was randomized, but masking is listed as none. In general, random assignment can reduce systematic differences between groups at the point of assignment, while lack of masking may affect how outcomes are assessed or recorded. The primary outcome is based on absolute neutrophil count measurements, and the registry record identifies the investigator as the assessor for certain secondary outcomes. It does not report details of any independent outcome assessment.

The primary endpoint was assessed from randomization to the end of Cycle 1, with each cycle lasting 21 days. The primary analysis set included all randomized participants, including those who were randomized but never treated under the endpoint definition. The registry record lists the study status as terminated. It does not report the reason for termination, the original planned enrollment, the original sample-size assumptions, or the relationship between the planned and achieved enrollment.

The trial therefore provides randomized comparisons of the posted regimens, but its interpretation depends on the endpoint definitions and analyses reported for each outcome. The registry record lists 35 outcome measures and 14 analyses. Those entries do not, by themselves, establish which analyses were prespecified or how the analyses were prioritized.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Participants were screened within 28 days before the first dose of the treatment. Informed consent was obtained up to 28 days prior to first study drug administration. For tumor assessment, all sites of disease were assessed radiologically at screening. A total of 102 participants were randomized in this study.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: The ITT analysis set included all randomized participants.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: The ITT analysis set included all randomized participants.

6. Primary Endpoint

The registry lists the primary outcome as Duration of Severe (Grade 4) Neutropenia (DSN) During Cycle 1, measured over From randomization to the end of Cycle 1 (Each cycle= 21 days).

The primary endpoint was the duration of severe, Grade 4 neutropenia during Cycle 1, measured in days. Neutropenia is represented in the endpoint definition by absolute neutrophil count (ANC). The duration starts with the first ANC value below 0.5 × 10^9 cells per liter observed between Day 1 of Cycle 1 and the end of that cycle. It ends at the first subsequent ANC value at or above 0.5 × 10^9 per liter, provided there are no intervening values below that threshold before the cycle ends. The registry record sets the duration to zero for participants who did not experience severe neutropenia during Cycle 1, including randomized participants who were never treated.

This endpoint captures both whether severe neutropenia occurred and, when it occurred, how long it lasted under the stated measurement rule. It is a continuous outcome, and the posted summaries use means and standard deviations. In general, a mean describes the group average, while a standard deviation describes variability among individual observations around that average.

The endpoint was chosen in the context of investigating potential bone-marrow preservation. It is not itself a measure of cancer response, survival, or overall treatment benefit. Because the endpoint definition assigns zero to people without the event, the mean combines zero-duration observations with positive durations. Interpretation should therefore remain tied to this definition rather than treating the mean as the average duration among only those who experienced severe neutropenia. The registry record does not report additional details about ANC measurement frequency or missing ANC values.

7. Results Posted in the Registry

• Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8): mean 2.00 versus 1.00 on control; difference 1.00 (95% CI -0.40 to 2.40), standardized effect d = 0.34; z-test p = 0.163.
• Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9): mean 1.00 versus 1.00 on control; difference 0.00 (95% CI -1.14 to 1.14), standardized effect d = 0.00; z-test p = 1.000.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Overall Survival (OS)

• Endpoint type: Time to event: compared as a hazard ratio.
• Test: Hazard ratio as reported by the sponsor (stratified log-rank test); it was not recalculated.
• Result:
  • Group 1: Gemcitabine/Carboplatin (Days 1 and 8) vs Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9): hazard ratio 0.40 (95% CI 0.22–0.74), reported p < 0.001 (as reported in the registry).
• Interpretation:
  • The 95% confidence interval excludes no difference (a ratio of 1), so the hazard of the event is statistically lower for Group 1: Gemcitabine/Carboplatin (Days 1 and 8) vs Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Number of Cycles Participants Received Treatment in Each Treatment Arm

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8): mean 9.00 versus 6.00 on control; difference 3.00 (95% CI 0.12 to 5.88), standardized effect d = 0.51; z-test p = 0.041.
  • Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9): mean 8.00 versus 6.00 on control; difference 2.00 (95% CI -0.39 to 4.39), standardized effect d = 0.41; z-test p = 0.102.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the mean is statistically higher for Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) and the control. The interval gives the range of effects that remain compatible with the data.

Cumulative Dose of Gemcitabine

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8): mean 14,681 versus 10,694 on control; difference 3,987 (95% CI -1,111 to 9,085), standardized effect d = 0.38; z-test p = 0.125.
  • Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9): mean 13,277 versus 10,694 on control; difference 2,583 (95% CI -1,752 to 6,918), standardized effect d = 0.29; z-test p = 0.243.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Group 2: Trilaciclib + Gemcitabine/Carboplatin (Days 1 and 8) and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) and the control. The interval gives the range of effects that remain compatible with the data.

The registry record lists secondary outcomes spanning tumor response, progression-free survival, overall survival, treatment exposure, treatment cycles, and gemcitabine and carboplatin dosing. These outcomes provide different perspectives on the study, but they do not all measure the same clinical or statistical construct. The survival analyses concern time until an event, while cycle and dose outcomes describe treatment received, and response outcomes concern tumor assessment.

The posted secondary results contain a mixture of estimates and degrees of uncertainty. The survival analyses include sponsor-reported hazard ratios and confidence intervals, while the treatment-exposure measures include group averages and variability. This broad pattern does not amount to a single overall secondary finding. Nor can secondary results substitute for the primary Cycle 1 endpoint: the outcomes have different definitions, timeframes, analysis methods, and participant sets.

In general, secondary outcomes are useful for describing the wider evidence from a trial, but they carry less weight when many outcomes or comparisons are examined without a reported plan to control multiplicity. Repeated testing increases the chance that some results appear notable by chance. The registry record does not report a multiplicity adjustment or a hierarchy that establishes which secondary hypotheses should be considered confirmatory. Secondary p-values should therefore be read as outcome-specific evidence rather than as a set of independent confirmations.

The secondary findings can help identify questions for further study, but they do not resolve the limitations of the primary estimate. They also cannot establish why the trial was terminated; the reason is not reported in the registry record. The overall interpretation should give priority to the defined primary endpoint and the uncertainty in its reported comparisons, while treating the secondary outcomes as additional, exploratory context unless a prespecified confirmatory plan is documented.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Number of Participants With Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
• Duration of Objective Response (DOR) as Per RECIST v1.1 as Determined by Investigator
• Overall Survival (OS)
• Progression Free Survival (PFS) as Per RECIST v1.1 as Determined by Investigator
• Relative Dose Intensity of Gemcitabine and Carboplatin
• Duration of Exposure
• Number of Cycles Participants Received Treatment in Each Treatment Arm
• Cumulative Dose of Gemcitabine

9. Statistical Interpretation

10. Statistical Methods Explained

The primary measure is a continuous outcome: a number of days, averaged across participants in each group. The registry record reports group means and standard deviations, and it reports ANCOVA as the sponsor’s method for the primary comparisons. Separate unadjusted calculations use the posted means, standard deviations, and group sizes. Those approaches answer related but not identical statistical questions.

What does a mean difference describe?

A mean difference expresses the estimated gap between two group averages in the outcome’s original unit, days. The recalculated comparison uses the chemotherapy-only group as the reference and contrasts it with each trilaciclib schedule. A positive difference in the comparisons as displayed corresponds to a higher mean in the trilaciclib group. The calculation is unadjusted: it compares the posted summaries without accounting for other participant characteristics or covariates.

In general, an unadjusted comparison can be useful as a transparent description of group summaries, but it may not reproduce a model-based analysis. ANCOVA, or analysis of covariance, estimates a group contrast while incorporating covariates specified in the analysis. The registry record identifies ANCOVA for the sponsor’s primary comparisons, but the covariates and further modeling details are not reported in the registry record. It is therefore not possible to reconstruct that adjusted analysis from the information reported.

What does a standard deviation tell the reader?

In general, the standard deviation describes how dispersed participant outcomes are around the group mean. It is not a confidence interval for the mean and it is not the range of individual observations. The primary endpoint includes zero for participants without severe neutropenia, as well as positive durations for those who meet the event definition. The standard deviations therefore describe variation across that combined set of values, not only among participants who experienced severe neutropenia.

In general, continuous outcomes with many zero values or a strongly uneven distribution can be difficult to summarize fully with a mean and standard deviation. The registry record does not report the outcome distribution, a median, a transformation, or a sensitivity analysis for the primary endpoint. It also does not report whether any alternative model was used to address skewness or other distributional features. These omissions limit assessment of how well the reported mean-based methods fit the observed data.

How should the confidence intervals and p-values be read?

In general, a confidence interval gives a range of values reasonably compatible with the data under the analysis assumptions and method. It conveys uncertainty around an estimated effect; it does not give the probability that the true effect lies inside that specific interval. A p-value describes how unusual data at least as discrepant as those observed would be under a specified null hypothesis and model. It is not the probability that the null hypothesis is true, and it does not measure clinical importance.

The recalculated p-values are unadjusted and accompany simple comparisons of posted summaries. The sponsor’s p-values accompany ANCOVA estimates. Neither set of values should be detached from its method. In general, an interval that spans zero is compatible with no mean difference as well as differences on either side, at the confidence level used. An interval’s width also matters: a broad interval leaves more possible effect sizes unresolved than a narrow one.

What does randomization contribute?

In general, random assignment supports comparisons by making treatment assignment independent of participant characteristics in expectation. It does not guarantee that groups are identical, especially in a trial of this size, and it does not correct problems arising after assignment, such as missing measurements or differing follow-up. The primary analysis population is listed as all randomized participants. The registry record does not report detailed adherence, missing-data handling, or whether additional analysis populations were used for this endpoint.

The trial is open-label, so participants and study personnel were not masked to assignment. In general, this may matter more for outcomes involving judgment than for a laboratory threshold, but it can still affect treatment exposure, measurement processes, or availability of assessments. The registry record does not describe monitoring procedures intended to limit such influences.

What is distinct about the survival method?

For overall survival, the registry record reports a stratified log-rank test and adjusted hazard ratios in the sponsor analyses. In general, survival methods account for the timing of events and for participants whose event status is not observed by the end of follow-up. A hazard ratio compares event rates over time under the model and assumptions used; it is not a difference in median survival time. Stratification means the analysis accounts for specified strata, but the strata are not reported in the registry record.

These methods differ from the mean-based analysis of Cycle 1 neutropenia. A survival hazard ratio and a mean difference in days describe different estimands and should not be combined as though they were measurements of the same outcome. The registry record does not report the details needed to independently reproduce the adjusted survival analyses.

11. Confidence Intervals and Precision

Precision is about how narrowly the data estimate an effect, not whether an effect is important. The sponsor’s ANCOVA comparison of chemotherapy alone with the trilaciclib schedule on Days 1 and 8 has a 95% confidence interval from -0.6 to 2.3 days. The comparison with the schedule that moved chemotherapy to Days 2 and 9 has a 95% confidence interval from -0.8 to 1.5 days. Each interval includes zero and allows values on either side of no mean difference. The intervals therefore do not pin down a single direction or a narrowly defined effect size.

The recalculated unadjusted interval for the Days 1 and 8 schedule runs from -0.405 to 2.405 days; for the schedule with chemotherapy on Days 2 and 9 it runs from -1.135 to 1.135 days. These are not the same estimates as the ANCOVA results. They are unadjusted recalculations from posted summary statistics, while the registry’s sponsor analyses use ANCOVA. Their differing endpoints and widths reflect that distinction as well as the reported precision.

In general, confidence intervals are more informative than a p-value alone because they show a range of effect magnitudes compatible with the analysis. An interval that crosses zero does not prove the absence of a difference. It indicates that the analysis does not clearly distinguish a difference from no difference at the stated confidence level. Nor does it rule out potentially meaningful values unless the interval is narrow enough relative to a prespecified threshold. A threshold for clinical importance is not reported in the registry record.

The standard deviations, 2.2, 3.5, and 2.6 days, also show that individual values vary within each group. In general, a group mean can be estimated with greater precision than individual outcomes are consistent, but the precision depends on both variability and sample size. The endpoint’s zero assignment for participants without severe neutropenia also shapes the group distribution. The registry record does not provide additional distributional summaries or missing-data analyses that would further characterize uncertainty.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning figures for the primary mean-difference comparison are participants per arm, not totals across both arms. The survival planning figures are total events. For the primary endpoint, the illustration uses a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. It sets the effect to detect as a stated fraction of the observed effect. For survival, the planning figures use the total number of events and the Schoenfeld approach.

The 80% power column describes the number of participants per arm in the primary-endpoint illustration that would correspond to an 80% chance of detecting the specified effect under the stated planning assumptions, if that effect and the assumptions were correct. The 90% column describes the corresponding planning target for a 90% chance. In the survival illustration, the values are event counts rather than participants per arm. The distinction matters because the number of events needed is not the same as a total enrollment target; the registry record does not give a conversion from events to enrollment for these illustrations.

Each row applies a different fraction of the observed effect. Planning for 75% of the observed effect requires more participants than planning for the full observed effect, and planning for 50% requires still more. In general, smaller effects are harder to distinguish from random variation, so they require larger samples for the same power target. The figures are planning illustrations based on observed effects, not the trial’s original design justification. Original sample-size assumptions are not reported in the registry record. These figures are not observed power.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = 1.000; pooled standard deviation σ = 2.913.
2. n = 2 × (1.96 + 0.842)² × 2.913² / 1.000² = 133.2, rounded up to 134 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- 1                      # observed difference in means
sigma <- 2.91341723754082                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(2978716)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 134 (80% power), 179 (90% power)
 75% of observed effect: n per arm = 237 (80% power), 318 (90% power)
 50% of observed effect: n per arm = 533 (80% power), 714 (90% power)
power.t.test: 134.2 
Simulated power at n = 134 per arm: 0.798 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Analyses Reported by the Sponsor

The sponsor’s own primary analyses are reported as ANCOVA comparisons. For chemotherapy alone versus trilaciclib with chemotherapy on Days 1 and 8, the reported mean difference is 0.8 days, with a 95% confidence interval from -0.6 to 2.3 and p=0.336. For chemotherapy alone versus the schedule with chemotherapy on Days 2 and 9, the reported mean difference is 0.3 days, with a 95% confidence interval from -0.8 to 1.5 and p=0.705.

The recalculations use posted group means and standard deviations to estimate simple, unadjusted differences. They do not reproduce the sponsor’s ANCOVA, whose covariates are not reported in the registry record. The numerical estimates and p-values consequently differ. The sponsor analysis is the registry’s reported model-based analysis; the recalculations offer a separate, transparent comparison derived from group summaries, not a replacement or correction to that model.

Both sponsor confidence intervals include zero. The analyses therefore do not provide a clear separation from no mean difference at the stated confidence level. That observation is about statistical uncertainty, not proof that the regimens are equivalent. An equivalence margin or noninferiority margin is not reported in the registry record.

15. Multiplicity, Missing Data and Analysis Populations

The registry record lists 35 outcome measures and 14 analyses, including several secondary outcomes and comparisons across treatment groups. When multiple outcomes and comparisons are assessed, the chance of obtaining at least one seemingly notable result by chance can increase. In general, a prespecified multiplicity strategy can limit that problem by defining which comparisons are primary, how testing is ordered, or how the threshold for interpreting results is adjusted.

A multiplicity strategy is not reported in the registry record. The record also does not report a statistical analysis plan describing the prespecified hierarchy of outcomes, the planned handling of multiple comparisons, or whether the posted analyses were selected from a broader set. Without that information, the reported p-values should not be read as though they necessarily control the overall error rate across all outcomes and comparisons. This is particularly relevant to secondary results, which cover several distinct domains.

The primary analysis population is described as the intention-to-treat set, including all randomized participants. The endpoint definition sets severe neutropenia to zero for randomized participants who were never treated. This defines how that particular situation is handled for the outcome. It does not establish how missing ANC measurements, incomplete follow-up, or other missing endpoint information were handled. Those methods are not reported in the registry record.

The registry record does not report the extent or pattern of missing primary outcome data, imputation methods, sensitivity analyses, or the reasons for missingness. In general, missing-data methods matter because estimates can be biased if the availability of measurements is related to outcomes or treatment assignment. The record also does not state whether any per-protocol or treated-population sensitivity analyses were performed for the primary endpoint. The posted intention-to-treat definition is therefore important, but it does not answer every question about how the analysis handled unavailable measurements.

Some secondary outcomes have participant counts that differ from the randomized group sizes. The registry record does not give a full explanation of the analysis population for every measure or the reasons for those differences. Without that detail, comparisons across endpoints should be cautious: differing denominators may reflect outcome-specific eligibility or data availability, but the reason is not reported in the registry record. The reason for the terminated status is also not reported.

16. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: cellulitis (6.7%), platelet count decreased (6.1%), pleural effusion (6.1%), pulmonary embolism (6.1%), hypertension (3.3%).

The registry record reports serious adverse event figures by group. The counts recorded as at risk were 30 for chemotherapy alone, 33 for trilaciclib with chemotherapy on Days 1 and 8, and 35 for the schedule with trilaciclib on Days 1, 2, 8, and 9. The corresponding numbers with serious adverse events were 10, 11, and 4. These are counts, not estimates of comparative risk adjusted for follow-up or participant characteristics.

The registry record also lists deaths of 25, 13, and 20 across the three groups, respectively. These figures are reported as deaths, and the registry record does not establish that they were caused by study treatment. The timing, causes, and relationship to treatment are not reported in the information summarized for these results. They should not be interpreted as treatment-attributable deaths.

Serious adverse events are distinct from other adverse events. The reported serious-event terms with the highest listed percentages include cellulitis at 6.7%, platelet count decreased at 6.1%, pleural effusion at 6.1%, pulmonary embolism at 6.1%, hypertension at 3.3%, and hypotension at 3.3%. In general, adverse-event counts and percentages require context about definitions, exposure time, follow-up, and event attribution. The registry record does not provide enough detail to make causal comparisons from these figures alone.

17. What the Result Does, and Does Not, Mean

The primary endpoint results estimate group differences in the mean duration of severe neutropenia during Cycle 1, under the registry’s specific definition. The sponsor-reported ANCOVA intervals include zero, and the unadjusted recalculations likewise do not establish a clear difference from zero. These results describe uncertainty in the posted analyses; they do not prove that the regimens have identical effects or that any difference is clinically unimportant.

The outcome is a blood-count measure, not a direct measure of cancer control, quality of life, or survival. The registry record describes the study’s broader aims, but the primary result alone cannot establish whether trilaciclib altered tumor outcomes or overall benefit. Secondary survival and response outcomes address other questions and have their own analytic assumptions and uncertainties. In general, evidence on one endpoint cannot automatically be transferred to another.

The randomized design supports comparisons among the assigned regimens, but the open-label status, missing-data details not reported, and absence of a reported multiplicity strategy all matter to interpretation. The registry record does not report the original sample-size justification, analysis covariates for ANCOVA, or the reason for termination. Those gaps limit assessment of the planned inferential framework and the completeness of the posted analyses.

The numerical estimates are compatible with a range of possible group differences. The confidence intervals express that imprecision and should be considered alongside the study’s sample sizes and variability. They do not provide a probability that the treatment has a particular effect, and a p-value does not measure the importance of an effect. Equivalence or noninferiority cannot be concluded because such margins are not reported in the registry record.

Accordingly, the results are best understood as estimates from a randomized Phase 2 trial of specific treatment schedules. They do not, by themselves, support broad claims about treatment efficacy or safety beyond the outcomes and comparisons reported. The registry record’s terminated status is a descriptive status; its reason and implications for the evidence are not reported.

18. Why This Trial Matters Statistically

Statistically, this trial is useful because it presents randomized comparisons of chemotherapy alone with two distinct schedules that add trilaciclib. The comparison is not simply between exposure and no exposure: the third group also shifts chemotherapy days. Keeping the schedules distinct is essential when interpreting any contrast, because the estimates correspond to the regimens actually assigned.

The primary endpoint illustrates why effect estimates and uncertainty should be read together. The group means alone suggest different observed averages for one schedule, but the reported confidence intervals span no difference and values on either side. A point estimate is only one estimate from the data; it does not convey how much uncertainty surrounds it. The sponsor’s adjusted model and the summary-statistic recalculations also demonstrate that analysis methods can yield different estimates.

The trial’s multiple outcome domains make clear why analysis plans matter. Survival, response, treatment cycles, dosing, and severe neutropenia answer different questions. Without a reported multiplicity strategy or complete analysis plan, a reader should avoid treating a pattern of secondary p-values as a collection of independent confirmations. This is a general issue in clinical trials with multiple outcomes, not a claim about why any particular result occurred.

The registry record also makes the analysis population and endpoint rule visible: the primary population includes all randomized participants, and those without severe neutropenia are assigned zero duration. These details define what the mean represents. At the same time, unreported details about missing measurements and model covariates show why concise registry results are not a substitute for a full protocol and statistical analysis plan.

19. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary endpoint is summarized with a mean and standard deviation, but the registry record does not report the distribution of individual durations or additional summaries that would show how the zero values and positive durations are distributed. Because the endpoint assigns zero to participants without severe neutropenia, the mean reflects both event occurrence and duration. The posted mean cannot be interpreted as the average duration among event cases alone.

The sponsor reports ANCOVA, but the covariates and model details are not reported in the registry record. This prevents independent reconstruction of the adjusted comparisons and makes it difficult to determine which baseline factors were accounted for. The unadjusted recalculations are informative as summary-based comparisons, but they answer a different question from the adjusted model.

The primary analysis set is defined as all randomized participants, yet the extent of missing ANC measurements and the handling of missing primary outcome data are not reported. The record also does not report whether sensitivity analyses examined alternative assumptions about missingness or the outcome distribution. These omissions matter because conclusions can depend on which participants contribute usable measurements and how incomplete observations are treated.

The study was open-label and terminated. The reason for termination, the original sample-size justification, and any changes to planned outcomes or analyses are not reported in the registry record. The record also does not report a multiplicity plan, a clinical importance threshold for the primary endpoint, or the details needed to judge whether the posted secondary findings were confirmatory.

Finally, the adverse-event counts do not provide a full causal safety comparison. Details about event timing, exposure duration, attribution, and causes of deaths are not reported in the results summarized. Differences in counts should not be interpreted as treatment effects without that context.

20. Related Tutorials

21. Related Statistical Calculators

22. Sources

• ClinicalTrials.gov: Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) — NCT02978716.
• Registry record last updated 2022-03-23; status last verified 2022-02.
• Results first posted 2022-03-23.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

23. Record Summary

NCT02978716 was a randomized, open-label, parallel-group Phase 2 study of trilaciclib with gemcitabine and carboplatin in metastatic triple-negative breast cancer. The registry record reports enrollment of 102 participants assigned to chemotherapy alone or one of two trilaciclib schedules.

The primary endpoint was duration of severe, Grade 4 neutropenia during Cycle 1. The sponsor-reported ANCOVA comparisons had confidence intervals that included zero. The registry record also reports secondary outcomes covering survival, response, and treatment exposure, as well as serious adverse event counts.

The record lists the study status as terminated. Its reason, the original sample-size assumptions, the ANCOVA covariates, missing-data methods, and a multiplicity strategy are not reported in the registry record. Results should be interpreted as estimates for the specific regimens, endpoints, populations, and methods described.